“...it seems very likely that mRNA will be one of the tools that helps us to develop new combination vaccines, especially against respiratory viruses.”
With vaccination against influenza, SARS-CoV-2, and RSV now recommended for at-risk adults, momentum is building for new combination respiratory vaccines. However, the path to the clinic remains challenging. Here, I outline some of the key benefits and complexities of bringing combination vaccines to market—from the perspective of a respiratory medicine clinician and researcher.
On January 28, 2025, Charlotte Barker, Commissioning Editor, Vaccine Insights, spoke to Angela Branche, Associate Professor of Medicine, University of Rochester, about the concept of an adult respiratory virus combination vaccine and the difficulties of taking combination vaccines into clinical trials. This article has been written based on the interview.
